| Data Type | Variable Name | Full Model | Model Without Medical Information | ||
|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | ||
| Demographics | Age | 1.015 | 1.012-1.017 | 1.017 | 1.015-1.020 |
| Female gender | 0.730 | 0.695-0.767 | 0.765 | 0.733-0.799 | |
| Health services use | Physician visits | 1.005 | 1.003-1.007 | ||
| Hospitalizations | 1.066 | 1.017-1.118 | |||
| Colonoscopy | 1.074 | 0.999-1.155 | |||
| Mammography | 1.206 | 1.137-1.280 | |||
| Vaccinations | 1.104 | 1.062-1.147 | |||
| Comorbidities | PVD | 0.885 | 0.787-0.996 | ||
| Prior liver disease | 0.869 | 0.783-0.964 | |||
| Renal dysfunction | 0.911 | 0.826-1.005 | |||
| Recent MI | 2.322 | 1.921-2.806 | |||
| Previous stroke | 1.833 | 1.471-2.285 | |||
| Ischemic heart disease | 1.163 | 1.081-1.252 | |||
| Diabetes | 0.905 | 0.835-0.980 | |||
| Cancer | 1.063 | 1,000-1.131 | |||
| Drug use | ACEIs | 0.997 | 0.950-1.047 | 0.982 | 0.936-1.031 |
| Antidiabetics | 0.922 | 0.848-1.003 | 0.834 | 0.790-0.881 | |
| Antiparkinson agents | 0.820 | 0.692-0.971 | 0.816 | 0.690-0.966 | |
| Antiplatelets | 0.886 | 0.791-0.993 | 0.957 | 0.859-1.066 | |
| ARBs | 0.869 | 0.819-0.923 | 0.885 | 0.834-0.938 | |
| Calcium channel blockers | 0.852 | 0.806-0.900 | 0.849 | 0.804-0.897 | |
| Digoxin | 0.724 | 0.569-0.922 | 0.742 | 0.583-0.945 | |
| Loop diuretics | 1.040 | 0.939-1.152 | 1.043 | 0.943-1.153 | |
| NSAIDs | 0.944 | 0.895-0.995 | 0.924 | 0.876-0.973 | |
| Oral anticoagulants | 1.304 | 1.157-1.471 | 1.415 | 1.259-1.591 | |
| SSRIs | 1.000 | 0.947-1.057 | 0.997 | 0.944-1.053 | |
| TCAs | 1.203 | 1.063-1.362 | 1.168 | 1.032-1.321 | |
| Thiazide diuretics | 0.987 | 0.938-1.039 | 0.976 | 0.927-1.027 | |
| Nonstatin lipid-lowering drugs | 1.490 | 1.354-1.641 | 1.486 | 1.351-1.634 | |
| Number of any drug | 1.008 | 1.005-1.010 | 1.010 | 1.008-1.012 | |
| Prescription burden | Number of unique drug type | 0.949 | 0.941-0.957 | 0.962 | 0.955-0.969 |
| Number of concurrently prescribed drugs as the index statin | 1.089 | 1.075-1.103 | 1.086 | 1.072-1.100 | |
| Number of drugs among those listed above | 0.999 | 0.996-1.002 | 0.998 | 0.995-1.001 | |
| Refill synchronization | 0.865 | 0.777-0.963 | 0.825 | 0.742-0.918 | |
| Sum of copayment for drugs | 1.000 | 1.000-1.000 | |||
| Benefit plan type | EPO vs. PPO | 0.722 | 0.635-0.820 | 0.723 | 0.636-0.821 |
| HMO vs. PPO | 0.896 | 0.783-1.026 | 0.900 | 0.787-1.030 | |
| IND vs. PPO | 1.072 | 0.917-1.253 | 1.052 | 0.901-1.228 | |
| Other vs. PPO | 1.155 | 0.662-2.012 | 1.184 | 0.680-2.064 | |
| POS vs. PPO | 0.906 | 0.805-1.020 | 0.904 | 0.804-1.017 | |
| Index statin information | Copay amount | 0.996 | 0.994-0.997 | 0.996 | 0.995-0.997 |
| Days supply | 1.007 | 1.006-1.008 | 1.006 | 1.005-1.007 | |
| High-dose statin (no vs. yes) | 1.289 | 1.192-1.394 | 1.219 | 1.129-1.317 | |
| Previous medication adherence | Mean PDC | 5.985 | 5.410-6.621 | 6.081 | 5.500-6.722 |
ACEI = angiotensin-converting enzyme inhibitors, ARBs = angiotensin II receptor blockers; CI = confidence interval; EPO = exclusive provider organization; HMO = health maintenance organization; IND = individual health plan; MI = myocardial infarction; NSAIDS = nonsteroidal anti-inflammatory drugs; OR = odds ratio; PDC = proportion of days covered; POS = point-of-service; PPO = preferred provider organization; PVD = peripheral vascular disease; SSRIs = selective serotonin reuptake inhibitors; TCAs = tricyclic antidepressants.